Our data outlined six proteins that show remarkable differences in abundance across the subtypes and are also FDA‐approved drug targets, namely DDC (overexpressed in SCLC‐A), EPHA2, ITAV and ITB1 (corresponding to genes EPHA2, ITGAV and ITGB1, overexpressed in SCLC‐Y), HDAC1 (downregulated in SCLC‐Y) and KIT (upregulated in SCLC‐P). Here, HDAC1 is linked to small cell lung carcinoma.